12
Treatment
Antipsychotic medications: available oral and short-acting
intramuscular formulations*
Genric name
Trade name
(most common in
U.S., may change)
Metabolic enzymes/
transporters
Available U.S.
formulations
(mg, unless otherwise
noted)
Second-generation antipsychotics
Aripiprazole
Abilify
CYP2D6 (Major), CYP3A4
(Major) substrate
Tablet: 2, 5, 10, 15, 20, 30
Tablet, disintegrating: 10, 15
Tablet with ingestible event
marker (Mycite): 2, 5, 10,
15, 20, 30
Solution: 1/mL (150 mL)
Asenapine
Saphris
CYP1A2 (Major), CYP2D6
(Minor), CYP3A4 (Minor)
substrate; glucuronidation
by UGT1A4; CYP2D6 weak
inhibitor
Tablet, sublingual: 2.5, 5, 10
Asenapine
Secuado
CYP1A2 (Major), CYP2D6
(Minor), CYP3A4 (Minor)
substrate; glucuronidation
by UGT1A4; CYP2D6 weak
inhibitor
Transdermal system:
3.8 mg/24 hours,
5.7 mg/24 hours,
7.6 mg/24 hours
Brexpiprazole
Rexulti
CYP3A4 (Major), CYP2D6
(Major) substrate
Tablet: 0.25, 0.5, 1, 2, 3, 4
Cariprazine
Vraylar
CYP3A4 (Major), CYP2D6
(Minor) substrate
Capsule: 1.5, 3, 4.5, 6
Clozapine
c
Clozaril, FazaClo,
Versacloz
CYP1A2 (Major), CYP2A6
(Minor), CYP2C19 (Minor),
CYP2C9 (Minor), CYP2D6
(Minor), CYP3A4 (Minor)
substrate
Tablet: 25, 50, 100, 200
Tablet, disintegrating:
12.5, 25, 100, 150, 200
Oral suspension: 50/mL
(100 mL)
Iloperidone
Fanapt
CYP2D6 (Major), CYP3A4
(Minor) substrate, CYP3A4
weak inhibitor
Tablet: 1, 2, 4, 6, 8, 10, 12
Lurasidone
Latuda
CYP3A4 (Major) substrate,
CYP3A4 weak inhibitor
Tablet: 20, 40, 60, 80, 120
Olanzapine
Zyprexa
CYP1A2 (Major), CYP2D6
(Minor) substrate;
metabolized via direct
glucuronidation
Tablet: 2.5, 5, 7.5, 10, 15, 20
Tablet, disintegrating:
5, 10, 15, 20
Short-acting IM powder for
solution: 10/2 mL
(cont'd)
